Mounjaro

News

Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.

News

A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.

News

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

News

Eli Lilly's LillyDirect, an important driver of sales of its weight-loss drugs in the US, has now arrived in the UK – with modifications.

News

France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.